Per Nived
1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs : a Swedish nationwide study (COVID-19-REUMA)
(
- Contribution to journal › Article
- 2023
-
Mark
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
(
- Contribution to journal › Article
- 2022
-
Mark
Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients
(
- Contribution to journal › Article
- 2021
-
Mark
Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients. From antibody response to memory cells.
2021) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Methotrexate reduces circulating Th17 cells and impairs plasmablast and memory B cell expansions following pneumococcal conjugate immunization in RA patients
(
- Contribution to journal › Article
- 2020
-
Mark
Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
(
- Contribution to journal › Article
- 2018
-
Mark
Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment
(
- Contribution to journal › Article
- 2017
-
Mark
Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy
(
- Contribution to journal › Article